Heat Biologics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heat Biologics stock.
View analyst ratings for Heat Biologics or view top-rated stocks.

Wall Street analysts have given Heat Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heat Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Heat Biologics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Heat Biologics.

Heat Biologics, Inc. (NASDAQ:HTBX) posted its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.02. The biopharmaceutical company earned $0.54 million during the quarter, compared to analysts' expectations of $0.57 million. Heat Biologics had a negative net margin of 1,055.71% and a negative trailing twelve-month return on equity of 26.09%.
View Heat Biologics' earnings history.

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HTBX stock has increased by 991.4% and is now trading at $7.64.
View which stocks have been most impacted by COVID-19.

Heat Biologics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

4 equities research analysts have issued 12 month target prices for Heat Biologics' stock. Their forecasts range from $4.00 to $32.00. On average, they anticipate Heat Biologics' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price.
View analysts' price targets for Heat Biologics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Heat Biologics include Enanta Pharmaceuticals (ENTA), Gracell Biotechnologies (GRCL), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), OrganiGram (OGI), Amphastar Pharmaceuticals (AMPH), BioXcel Therapeutics (BTAI), PyroGenesis Canada (PYR), G1 Therapeutics (GTHX), ESSA Pharma (EPIX), Syndax Pharmaceuticals (SNDX), Merus (MRUS), Arcturus Therapeutics (ARCT), Zomedica (ZOM) and Radius Health (RDUS).
View all of HTBX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.90%), Geode Capital Management LLC (0.76%), Principal Financial Group Inc. (0.60%), Principal Financial Group Inc. (0.60%), IndexIQ Advisors LLC (0.23%) and HRT Financial LP (0.18%). Company insiders that own Heat Biologics stock include Edward B Smith III and John K A Prendergast.
View institutional ownership trends for Heat Biologics.

HTBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Los Angeles Capital Management LLC, and HRT Financial LP. Company insiders that have sold Heat Biologics company stock in the last year include Edward B Smith III, and John K A Prendergast.
View insider buying and selling activity for Heat Biologics or view top insider-selling stocks.

HTBX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., IndexIQ Advisors LLC, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Sigma Planning Corp, Trexquant Investment LP, Virtu Financial LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Heat Biologics or or view top insider-buying stocks.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HTBX stock can currently be purchased for approximately $7.64.

Heat Biologics has a market capitalization of $192.91 million and generates $2.95 million in revenue each year.

Heat Biologics employs 39 workers across the globe.

The official website for Heat Biologics is www.heatbio.com.

Heat Biologics is headquartered at 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560.

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]